Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | MURANO: venetoclax + rituximab in BIRC3-mutated R/R CLL

Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, updates us on the results of the MURANO study (NCT02005471), investigating the effect of fixed-duration venetoclax plus rituximab in BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia (CLL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).